Clinical trials to begin on potent angiogenesis inhibitors

BMJ 1998; 316 doi: (Published 09 May 1998) Cite this as: BMJ 1998;316:1407
  1. Kamran Abbasi
  1. BMJ

    Two new drugs that inhibit the blood supply to tumours are to undergo clinical trials in humans. A statement by the US National Cancer Institute that research on endostatin and angiostatin is “a high priority” sent the share price of the manufacturer of the drugs, Entremed, soaring and caused massive public interest.

    In one day …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription